In This Article:
By M. Marin
NASDAQ:QNRX
READ THE FULL QNRX RESEARCH REPORT
Positive interim clinical data
Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, initially in the dermatology space. The company is advancing clinical studies to evaluate lead asset QRX003 for the treatment of Netherton Syndrome (NS). Quoin has active NS studies that are being conducted concurrently under an open Investigational New Drug (IND) application with the FDA. The company believes it is the only development company developing treatment for NS that is conducting dual studies concurrently under an open IND application. Two U.S. trials utilize the same investigators and clinical sites, which Quoin expects will result in substantial operational synergies and cost savings. QNRX is also assessing QRX003 in an NS pediatric patient in an Investigator Pediatric NS study, with plans to enroll additional pediatric patients at other sites.
Key takeaways
-
QNRX is advancing clinical studies to evaluate lead asset QRX003 for treatment of Netherton Syndrome (NS), a debilitating skin disorder.
-
Interim results are positive, with no adverse events reported to-date.
-
4-weeks after QRX003 treatment ended, all benefits of QRX003 treatment were reversed, which QNRX believes indicates the need for continuous treatment.
-
Quoin is optimistic that QRX003 can become the 1st approved treatment for NS. As with all of Quoin's assets, QRX003 is being designed to treat multiple indications.
-
To raise awareness of NS, QNRX has launched the NETHERTON NOW campaign.
Quoin reported positive early results from its current study of QRX003 for pediatric NS patients last week. The company noted that dramatic improvement was observed in the patient following treatment, with what it termed “clear visual evidence of skin healing” after two weeks of whole-body application of QRX003. Moreover, no adverse events have been reported to-date.
Following QRX003 treatment, the patient has discontinued alternative NS medications used previously, including all antihistamines, glucocorticoids and antivirals and also has not needed antibiotics. The company also noted that for the first time ever, the pediatric patient is not having any sleep disturbances.
The clinical assessment of QRX003 in a pediatric patient is being led by Dr. Alan Irvine, a professor of dermatology at Trinity College Dublin and a Consultant Dermatologist at Children’s Health Ireland. Dr. Irvine is also the president of the International Eczema Council and an elected member of the Royal Irish Academy. He has authored more than 250 peer-reviewed papers published in medical journals. QNRX expects to broaden the scope of this clinical assessment to include three additional pediatric patients in Spain. Following a recent share offering, it has extended its cash runway to advance clinical studies.